About: SPC manufacturing waiver
Pharma industry raises the alarm about stockpiling of generic drugs
The industry of innovative medicines is concerned with a recent vote in the European Parliament on the stockpiling of generic drugs, saying that it causes uncertainty over innovation in the pharmaceutical field.
Discussion heats up over stockpiling of generic drugs under patent protection
The Commission has announced its intention to add a manufacturing waiver to supplementary protection certificates (SPC), as part of its upgraded 2015 Single Market Strategy.
The European Commission should shelve its patent law proposal
The European Commission is considering an initiative that would permanently hobble the continent's economy, writes Jan Fischer.
Protecting the spark, avoiding the storm
Every new treatment, every transformational shift in the outlook for patients starts with the spark of an idea, writes Nathalie Moll.
EU generics industry slams US ‘intervention’ in SPC manufacturing waiver talks
The EU generics industry has accused the US government of intervening in the ongoing discussion in the EU on the introduction of a Supplementary Protection Certificate (SPC) manufacturing waiver.
EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation
The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.
Andriukaitis: SPC manufacturing waiver does not damage pharma innovation
The European Commission’s proposal to add an SPC manufacturing waiver on exports will not damage innovation, as the pharma industry claims, and only intends to support small and medium generic drug companies, according to EU Health Commissioner Vytenis Andriukaitis.
Pharma boss: Incentives based on outcomes will optimise EU healthcare
An outcomes-based approach for incentives in the pharmaceutical sector would help optimise the entire healthcare systems, Nathalie Moll told EURACTIV.com in an interview.
Generic industry boss: SPC manufacturing waiver won’t harm originators’ innovation
The generic industry’s request for an SPC (supplementary protection certificates) manufacturing waiver, which would allow them to produce in the EU SPC-protected drugs for other markets, does not influence or harm innovators’ rights, Marc–Alexander Mahl told EURACTIV.com in an interview. He...